Comparison of Methylation Profiling in Cancerous and Their Corresponding Normal Tissues from Korean Patients with Breast Cancer

Eun-Jung Jung, M.D.1, In-Suk Kim, M.D.2, Eun Yup Lee, M.D.2, Jeong-Eun Kang, M.D.3, Sun-Min Lee, M.D.3, Dong Chul Kim, M.D.4, Ju-Yeon Kim, M.D.1, and Soon-Tae Park, M.D.1

Division of Surgical Oncology1, Department of Surgery, Gyeongsang National University Hospital, Jinju; Department of Laboratory Medicine2, Biomedical Research Institute, Pusan National University Hospital, Busan; Department of Laboratory Medicine3, Pusan National University Yangsan Hospital, Yangsan; Department of Pathology4, Gyeongsang National University Hospital, Jinju, Korea

Background: Aberrant DNA hypermethylation plays a pivotal role in carcinogenesis and disease progression; therefore, accurate measurement of differential gene methylation patterns among many genes is likely to reveal biomarkers for improved risk assessment. We evaluated the gene hypermethylation profiles of primary breast tumors and their corresponding normal tissues and investigated the association between major clinicopathological features and gene hypermethylation.

Methods: A single reaction using methylation-specific multiplex ligation-dependent probe amplification was used to analyze the DNA methylation status of 24 tumor suppressor genes in 60 cancerous tissues and their corresponding normal tissues from patients with primary breast cancer.

Results: In cancerous breast tissues, 21 of 24 genes displayed promoter methylation in one or more samples. The most frequently methylated genes included RASSF1 (43.3%), APC (31.7%), CDKN2B (25.0%), CDH13 (23.3%), GSTP1 (16.7%), and BRCA1 (10%). APC was associated with lymph node metastasis, and BRCA1 was associated with negative estrogen receptor and negative progesterone receptor expression. In normal breast tissues, 8 of 24 tumor suppressor genes displayed promoter hypermethylation; CDKN2B (28.3%) and RASSF1 (8.3%) hypermethylation were most frequently observed.

Conclusions: RASSF1 and CDKN2B hypermethylation in Korean breast cancer patients were the most frequent in cancerous tissue and corresponding normal tissue, respectively. Our data indicates that methylation of specific genes is a frequent event in morphologically normal breast tissues adjacent to breast tumors as well as the corresponding breast cancers. This study also suggests that gene methylation is linked to various pathological features of breast cancer; however, this requires confirmation in a larger study.

Key Words: Breast cancer, Epigenetics, Carcinogenesis, Methylation

INTRODUCTION

Apart from thyroid cancer, breast cancer is the most common cancer among Korean women [1]. Genetic alterations associated with breast carcinogenesis, including specific gene amplifications, deletions, point mutations, chromosome rearrangements, and aneuploidy, are well understood. In addition to these highly characterized mutations, epigenetic alterations are key...
contributor to breast carcinogenesis [2-6]. The most widely studied epigenetic event in breast cancer is hypermethylation of CpG islands associated with the promoter regions of several genes [7, 8]. Hypermethylation of CpG islands in gene promoter regions is thought to be especially relevant for the silencing of important growth control genes. For breast cancer, some of the genes reported to undergo hypermethylation are involved in evasion of apoptosis (DAPK, TWIST1, and H0XA5), cell cycle regulation (CDKN2A and CCND2), cell invasion and metastasis (CDH1 and APC), DNA repair (BRCA1 and GSTP1), and cell signaling (ER and RARβ2) [2, 9]. These epigenetic alterations occur at an early stage in breast carcinogenesis.

However, most epigenetic studies have been performed on women in western countries, and the reported frequencies and disease specificities vary across the studies [3, 10-14]. These discrepancies most likely relate to differences in the populations studied, the methods used, and the genes and regions where methylation has been studied. Most of the methods used to detect methylation are labor-intensive and/or allow the study of the methylation status of only one gene at a time. In this study, we used an approach that allows the simultaneous assessment of aberrant promoter methylation of 24 tumor suppressor genes in normal and cancerous tissues from 60 Korean patients with primary breast cancer. The aims of this study were as follows: 1) to measure the frequency of gene hypermethylation in cancerous tissue and their corresponding normal tissue from Korean breast cancer patients and 2) to determine whether methylation changes in cancerous tissues from Korean breast cancer patients are associated with major clinicopathological features.

METHODS

1. Patients and tissue samples
This study was approved by the Institutional Review Board of the Gyeongsang National University Hospital (Jinju, Korea), and written informed consent was obtained from all patients participating in the study. We consecutively collected 60 pairs of cancerous and the corresponding normal tissue samples from patients with breast cancer. All samples were procured at the time of surgery, subjected to an initial gross pathological examination, frozen at -180°C in liquid nitrogen and stored until use. Corresponding normal tissues were procured from the most distant frozen at -180°C in liquid nitrogen and stored until use. Corresponding normal tissues were procured from the most distant frozen at -180°C in liquid nitrogen and stored until use. Matched normal and tumor tissues were processed separately to avoid possible contamination. Each sample was frozen at -180°C and broken with a frozen mortar. The homogenate was collected and resuspended in TE buffer (10 mM Tris/HCl and 1 mM EDTA)

DNA was extracted by proteinase K digestion, followed by heat inactivation at 95°C and phenol-chloroform and ethanol precipitation. DNA was quantified using a Nanodrop 1000 spectrophotometer (Thermo Scientific, Wilmington, DE, USA).

2. Tissue DNA extraction
Matched normal and tumor tissues were processed separately to avoid possible contamination. Each sample was frozen at -180°C and broken with a frozen mortar. The homogenate was collected and resuspended in TE buffer (10 mM Tris/HCl and 1 mM EDTA).

DNA was extracted by proteinase K digestion, followed by heat inactivation at 95°C and phenol-chloroform and ethanol precipitation. DNA was quantified using a Nanodrop 1000 spectrophotometer (Thermo Scientific, Wilmington, DE, USA).

3. Methylation-specific, multiplex ligation-dependent probe amplification assay
Gene methylation status was evaluated by methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) [17] by using the ME001-C1 Tumor suppressor-1 kit (MRC-Holland, Amsterdam, Netherlands). In all, 24 tumor suppressor genes and 12 internal control genes were studied using 50-100 ng of sample DNA (Table 2). In brief, during the first step of the assay, DNA samples were denatured and hybridized with target-specific MLPA probes by overnight incubation. Then, the reaction was split into 2 tubes. One tube was processed as the standard MLPA reaction, and the other tube was incubated with 10 U of HhaI at 49°C for 30 min. Digested probes are not amplified by PCR and, hence, do not generate a signal. In contrast, if the target DNA is methylated, the hemi-methylated probe/sample DNA hybrids are prevented from digestion by HhaI and the target region is amplified, generating a signal. The amplified products were analyzed by sequence-type capillary electrophoresis.
The methylation status was subsequently quantified by comparing the relative signal peaks from the 2 tubes by using the GeneMarker_V1.90 software (SoftGenetics, State College, PA, USA). Methylation was scored as positive when the calculated methylation levels were higher than 25%. Any value below that level was considered negative.

4. Sample size calculation and statistical analyses

Van der Auwera et al. [18] demonstrated a 58.9% difference in RASSF1A gene hypermethylation between cancerous and morphologically normal tissues (76.8% vs. 17.9%, respectively). Thus, it was estimated that 41 patients per group would be required to provide a power of 95% to detect a statistically significant difference between the cancerous and morphologically normal tissues in the Korean patients with breast cancer by using a two-sided \( \alpha \)-level of 0.05.

Continuous variables were presented as means±SD in baseline characteristics of patients with breast cancer (Table 1). For comparison of the methylation status of the 24 tumor suppressor genes in cancerous and corresponding normal tissues, data were presented as numbers and frequencies for categorical variables. The frequencies between groups were compared using the \( \chi^2 \)-test or, in the case of low frequency per variable, Fisher’s exact method. The Kappa statistic was used to assess the agreement between dichotomous variables between cancerous and corresponding normal breast tissue samples. The clinico-pathologic parameters using categorical variables and the hypermethylation status in cancerous tissues in patients with breast cancer were analyzed using the Pearson’s \( \chi^2 \)-test or Fisher’s exact method. A multivariate logistic regression analysis was used to identify independent predictors of clinico-pathologic characteristics among the hypermethylated genes. Factors entered into the multivariate model were those with a \( P \) value less than 0.10 from the univariate analysis. A \( P \) value ≤0.05 of two-sided test was considered statistically significant. All statistical calculations were performed using SPSS, version 13.0 (SPSS Inc., Chicago, IL, USA).

RESULTS

1. Methylation pattern of the 24 tumor-suppressor genes in cancerous tissue and their corresponding, morphologically normal breast tissue from patients with breast cancer

The distribution of DNA methylation of 24 tumor-suppressor genes in normal and cancerous breast tissues is shown in Fig. 1.
Twenty one of 24 genes (87.5%) displayed promoter hypermethylation in one or more of the cancerous tissues (Fig. 1A). However, only 8 of 24 tumor-suppressor genes (33.3%) displayed promoter hypermethylation in the normal tissue samples (Fig. 1B). In the cancerous breast tissues, the most frequently hypermethylated genes were \textit{RASSF1} (43.3%) followed by \textit{APC} (31.7%), \textit{CDKN2B} (25.0%), \textit{CDH13} (23.3%), \textit{GSTP1} (16.7%), and \textit{BRCA1} (10.0%). Methylation was not observed in the \textit{CD44}, \textit{CHFR}, and \textit{PTEN} gene promoters in cancerous tissues. In the normal breast tissues, the most frequently hypermethylated genes were \textit{CDKN2B} (28.3%) and \textit{RASSF1} (8.3%). In their cancerous tissues, the frequencies of \textit{RASSF1} (43.3% vs. 8.3%), \textit{APC} (31.7% vs. 0%), and \textit{CDH13} (23.3% and 5.0%) were significantly higher than those of normal tissues \((P<0.001, P<0.001, \text{and } P=0.004, \text{respectively}; \text{Table 2})\). However, the frequency of \textit{CDKN2B} (25.0%) in cancerous tissues was similar to that (28.3%) in corresponding normal tissue \((P=0.680)\).

In 65% of the cancerous tissues, the promoter regions were hypermethylated in at least one of the 21 hypermethylated genes. The results are summarized in Table 3. One tumor sample was methylated at 14 sites. In 38.3% of the normal tissues, the promoter regions were hypermethylated in at least 1 of the 8 hypermethylated genes (Table 1). None of the normal tumor samples were methylated at more than 5 sites.

### Table 2. Distribution of DNA hypermethylation of 24 tumor-suppressor genes in cancerous and corresponding normal breast tissues (N=60)

| Gene   | Gene full name                      | Chromosome location | Cancerous tissues, N (%) | Normal tissues, N (%) | \(P\) |
|--------|-------------------------------------|---------------------|--------------------------|-----------------------|-------|
| APC    | Adenomatosis polyposis coli         | 5q22                | 19 (31.7)                | 0 (0)                 | <0.001|
| ATM    | Ataxia telangiectasia mutated       | 11q23               | 1 (1.7)                  | 0 (0)                 | 1.000 |
| BRCA1  | Breast cancer 1                      | 17q21.31            | 6 (10.0)                 | 3 (5.0)               | 0.488 |
| BRCA2  | Breast cancer 2                      | 13q12.3             | 1 (1.7)                  | 0 (0)                 | 1.000 |
| CASP8  | Caspase 8                           | 2q33.2              | 1 (1.7)                  | 0 (0)                 | 1.000 |
| CD44   | CD44 molecule                       | 11p12               | 0 (0)                    | 0 (0)                 | 1.000 |
| CDH13  | Cadherin 13                         | 16q23.3             | 14 (23.3)                | 3 (5.0)               | 0.004 |
| CDKN1B | Cyclin-dependent kinase inhibitor 1B| 12p13.2             | 2 (3.3)                  | 0 (0)                 | 0.496 |
| CDKN2A | Cyclin-dependent kinase inhibitor 2A| 9p21                | 1 (1.7)                  | 0 (0)                 | 1.000 |
| CDKN2B | Cyclin-dependent kinase inhibitor 2B| 9p21                | 15 (25.0)                | 17 (28.3)             | 0.680 |
| CHFR   | Checkpoint with forkhead and ring finger domains | 12q24.33 | 0 (0) | 0 (0) | 1.000 |
| DAPK1  | Death-associated protein kinase 1    | 9q22                | 2 (3.3)                  | 0 (0)                 | 0.496 |
| ESR1   | Estrogen receptor                    | 6q25.1              | 3 (5.0)                  | 1 (1.7)               | 0.619 |
| FHT    | Fragile histidine triad gene         | 3p14.2              | 4 (6.7)                  | 1 (1.7)               | 0.364 |
| GSTP1  | Gluthathione S-transferase pi        | 11q13               | 10 (16.7)                | 2 (3.3)               | 0.015 |
| HIC1   | Hypermethylated in cancer 1          | 7p13.3              | 2 (3.3)                  | 0 (0)                 | 0.496 |
| IGSF4  | Immunoglobulin superfamily member 4  | 11q23               | 3 (5.0)                  | 0 (0)                 | 0.244 |
| MLH1   | mutL homolog I                       | 3p22.3              | 3 (5.0)                  | 0 (0)                 | 0.244 |
| PTEN   | Phosphatase and tensin homolog       | 10q23.3             | 0 (0)                    | 0 (0)                 | 1.000 |
| RARB   | Retinoic acid receptor beta          | 3p24.2              | 2 (3.3)                  | 0 (0)                 | 0.496 |
| RASSF1 | Ras association domain family 1A     | 3p21.3              | 26 (43.3)                | 5 (8.3)               | <0.001|
| TIMP3  | Tissue inhibitor of metalloproteinases 3| 22q12.3 | 1 (1.7) | 0 (0) | 1.000 |
| TP73   | Tumor protein p73                    | 1p36.32             | 4 (6.7)                  | 0 (0)                 | 0.119 |
| VHL    | von Hippel Lindau                    | 3p25.3              | 3 (5.0)                  | 1 (1.7)               | 0.619 |

2. Association between DNA hypermethylation and clinicopathological factors

We investigated the association of clinicopathological features of the patients with the 7 most frequently hypermethylated genes (\textit{RASSF1}, \textit{APC}, \textit{CDKN2B}, \textit{CDH13}, \textit{GSTP1}, \textit{BRCA1}, and \textit{FHT}) in cancerous tissues. Table 4 shows the association between the hypermethylation of these 7 genes and various clinicopathological features of the patients. \textit{RASSF1} hypermethylation showed a statistically significant association with the invasive ductal carcinoma tumor type vs. other tumor types (53.2% [25/47] vs. 7.7% [1/13], \(P=0.032\)); however, post-hoc comparisons among these
groups demonstrated no statistical significance between tumor types and RASSF1 hypermethylation. In addition, RASSF1 hypermethylation was associated with lymph node involvement (55.2% [16/29] vs. 32.2% [10/31], P=0.073), but the association was statistically insignificant. APC hypermethylation was associated with lymph node involvement (68.4% [13/29] vs. 19.3% [6/31], P=0.034). CDKN2B, CDH13, and GSTP1 hypermethylation were not associated with clinicopathological features. BRCA1 hypermethylation was associated with histologic grade III (25.0% [5/20] vs. 2.5% [1/40], P=0.013), negative ER expression (24.0% [6/25] vs. 0% [0/34], P=0.004), negative PR expression (20% [6/30] vs. 0% [0/29], P=0.014), and negative BCL-2 expression (20.8% [5/24] vs. 2.9% [1/34], P=0.046). The difference between the clinicopathological characteristics and BRCA1 hypermethylation in cancerous tissue was statistically significant as per the multivariate logistic regression analy-

Table 3. Distribution of DNA methylation of 24 tumor-suppressor genes in cancerous and corresponding normal breast tissues (N=60)

| Methylation | Cancerous tissues, N (%) | Normal tissues, N (%) | P  |
|-------------|--------------------------|-----------------------|----|
| Negative    | 21 (35.0)                | 37 (61.7)             | 0.003 |
| Positive    | 39 (65.0)                | 23 (38.3)             |    |
| N of methylation sites |             |                       |    |
| 1           | 9 (15.0)                 | 15 (25.0)             |    |
| 2           | 14 (23.3)                | 6 (10.0)              |    |
| 3           | 7 (11.7)                 | 1 (1.7)               |    |
| 4           | 2 (3.3)                  | 0 (0.0)               |    |
| 5           | 3 (5.0)                  | 1 (1.7)               |    |
| >5          | 4 (6.8)                  | 0 (0.0)               |    |
Table 4. Association between the methylation status in cancerous tissues and the clinicopathological characteristics in patients with breast cancer (N=60)

| Gene       | RASSF1 | APC     | CDKN2B  | CDH13   | GSTP1   | BRCA1   | FHIT    |
|------------|--------|---------|---------|---------|---------|---------|---------|
|            | Positive | Negative | Positive | Negative | Positive | Negative | Positive | Negative | Positive | Negative | Positive | Negative | Positive | Negative | Positive | Negative | Positive | Negative | Positive | Negative | Positive | Negative | Positive | Negative | Positive | Negative | Positive | Negative |
| Tumor type |         |         |         |         |         |         |         |
| Invasive ductal carcinoma | 25 | 22 | 18 | 29 | 11 | 36 | 12 | 35 | 10 | 37 | 5 | 42 | 4 | 43 |
| Ductal carcinoma in situ | 1 | 4 | 0 | 5 | 1 | 4 | 0 | 5 | 0 | 5 | 0 | 5 | 0 | 5 |
| Medullary carcinoma | 0 | 3 | 0 | 3 | 0 | 3 | 1 | 2 | 0 | 5 | 0 | 5 | 0 | 5 |
| Mucinous carcinoma | 0 | 5 | 1 | 4 | 3 | 2 | 1 | 4 | 0 | 3 | 1 | 2 | 0 | 3 |
| P          | 0.032  | 0.303  | 0.207  | 0.781  | 0.527  | 0.588  | 0.892  |
| Nodal involvement |         |         |         |         |         |         |         |
| Negative   | 10 | 21 | 6 | 25 | 5 | 26 | 6 | 25 | 3 | 28 | 3 | 28 | 0 | 31 |
| Positive   | 16 | 13 | 13 | 16 | 10 | 19 | 8 | 21 | 7 | 22 | 3 | 26 | 4 | 25 |
| P          | 0.073  | 0.034  | 0.101  | 0.451  | 0.175  | 1.000  | 0.049  |
| Stage      |         |         |         |         |         |         |         |
| I-ll       | 22 | 31 | 17 | 36 | 12 | 41 | 12 | 41 | 10 | 43 | 5 | 48 | 3 | 50 |
| III-IV     | 4 | 3 | 2 | 5 | 3 | 4 | 2 | 5 | 0 | 7 | 1 | 6 | 1 | 6 |
| P          | 0.454  | 1.000  | 0.351  | 0.660  | 0.589  | 0.541  | 0.399  |
| Histologic grade |         |         |         |         |         |         |         |
| 1-2        | 18 | 22 | 13 | 27 | 10 | 30 | 11 | 28 | 6 | 34 | 1 | 39 | 3 | 37 |
| 3          | 8 | 12 | 6 | 14 | 5 | 15 | 3 | 17 | 4 | 16 | 5 | 15 | 1 | 19 |
| P          | 0.713  | 0.844  | 1.000  | 0.347  | 0.718  | 0.013  | 1.000  |
| ER status  |         |         |         |         |         |         |         |
| Negative   | 8 | 17 | 6 | 19 | 5 | 20 | 8 | 17 | 2 | 23 | 6 | 19 | 2 | 23 |
| Positive   | 18 | 16 | 13 | 21 | 10 | 24 | 6 | 28 | 8 | 26 | 0 | 34 | 2 | 32 |
| Not available | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 |
| P          | 0.321  | 0.438  | 0.777  | 0.244  | 0.321  | 0.004  | 1.000  |
| PR status  |         |         |         |         |         |         |         |
| Negative   | 10 | 20 | 7 | 23 | 7 | 23 | 9 | 21 | 4 | 26 | 6 | 24 | 2 | 28 |
| Positive   | 16 | 13 | 12 | 17 | 8 | 21 | 5 | 24 | 6 | 23 | 0 | 29 | 2 | 27 |
| Not available | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 |
| P          | 0.232  | 0.304  | 1.000  | 0.258  | 0.747  | 0.014  | 1.000  |
| BCL-2      |         |         |         |         |         |         |         |
| Negative   | 8 | 16 | 6 | 18 | 4 | 20 | 6 | 18 | 3 | 21 | 5 | 19 | 0 | 24 |
| Positive   | 17 | 17 | 12 | 22 | 11 | 23 | 7 | 27 | 7 | 27 | 1 | 33 | 4 | 30 |
| Not available | 1 | 1 | 1 | 1 | 0 | 2 | 1 | 1 | 0 | 2 | 0 | 2 | 0 | 2 |
| P          | 0.247  | 0.449  | 0.588  | 1.000  | 0.757  | 0.046  | 0.341  |
| P53 status |         |         |         |         |         |         |         |
| Negative   | 4 | 7 | 4 | 7 | 4 | 7 | 2 | 9 | 2 | 9 | 2 | 9 | 0 | 11 |
| Positive   | 22 | 25 | 15 | 32 | 11 | 36 | 12 | 35 | 7 | 40 | 4 | 43 | 4 | 43 |
| Not available | 0 | 2 | 0 | 2 | 0 | 2 | 0 | 2 | 1 | 1 | 0 | 2 | 0 | 2 |
| P          | 1.000  | 0.539  | 0.314  | 1.000  | 1.000  | 0.333  | 0.624  |
| HER2/Neu status |         |         |         |         |         |         |         |
| Negative   | 15 | 14 | 12 | 17 | 7 | 22 | 9 | 20 | 6 | 23 | 5 | 54 | 3 | 26 |
| Positive   | 10 | 19 | 6 | 23 | 8 | 21 | 5 | 24 | 4 | 25 | 1 | 28 | 1 | 28 |
| Not available | 1 | 1 | 1 | 1 | 0 | 2 | 0 | 2 | 0 | 2 | 0 | 2 | 0 | 2 |
| P          | 0.358  | 0.325  | 1.000  | 0.180  | 0.539  | 0.126  | 0.381  |

Abbreviations: ER, estrogen receptor; PR, progesterone receptor.
sis. FHIT hypermethylation was associated with lymph node involvement (13.8% [4/29] vs. 0% [0/31], \(P=0.049\)).

We also investigated the 5 most frequently hypermethylated genes, CDKN2B, RASSF1, BRCA1, CDH13, and GSTP1, in the corresponding normal tissues and examined their association with clinicopathological features. CDKN2B hypermethylation was associated with positive ER expression (40.0% [12/30] vs. 13.8% [4/29], \(P=0.032\)) and positive PR expression (37.9% [11/29] vs. 16.7% [5/30], \(P=0.055\)). Hypermethylation of RASSF1, BRCA1, CDH13, and GSTP1 in the corresponding normal tissues was not associated with clinicopathological features (data not shown).

3. Concordant gene methylation in cancerous tissue and corresponding normal breast tissue

For most of the 24 tumor suppressor genes, there was a poor to slight agreement between methylation in cancerous and corresponding normal tissues. The results of the concordant methylation pattern and disconcordant methylation pattern in the cancerous and corresponding normal tissues are shown in Fig. 2A, B, respectively. When at least one gene(s) was found to be hypermethylated in normal and cancerous tissues, poor agreement was noted (data not shown).

**DISCUSSION**

Hypermethylation of CpG islands is a common mechanism for silencing tumor suppressor genes and occurs frequently in breast cancer. Although there is a large body of literature and the PubMeth online database (www.pubmeth.org) reporting tumor suppressor gene methylation frequency in breast cancer, methylation research of breast cancer in the Korean patients is still lacking, except for a few reports [5, 19, 20]. Several techniques exist to study aberrant methylation, i.e., methyl-specific PCR, bisulfite-dependent sequencing, and methyl-sensitive restriction enzyme-based assays. Most of these approaches are restricted to a limited number of genes. Although recent studies demonstrated that MS-MLPA analysis in breast cancer is relatively simple, sensitive, and highly specific to simultaneously detect the methylation status of multiple gene regions [17, 21-23], it is still necessary to confirm whether the MS-MLPA technique is an appropriate method to detect methylation.

In the present study, we investigated aberrant methylation of 24 genes in cancerous and their normal tissues from 60 Korean patients with breast cancer by using MS-MLPA. In the cancerous breast tissues, the most frequently hypermethylated genes were RASSF1 (43.3%), APC (31.7%), CDKN2B (25.0%), and CDH13 (23.3%). Using a PubMeth online database, which con-
tains information and statistics about DNA hypermethylation in various cancers, and a review of the literature, the frequency of RASSF1 hypermethylation of breast cancer was determined to be 72.0% [22] and 71.4% [4], respectively. In this study, the frequency of RASSF1 hypermethylation was 43.34% (26/60) in cancerous tissues of all types of breast cancer and 53.2% (25/47), in cancerous tissues of invasive ductal carcinoma. This value is somewhat lower than the frequencies reported in previous studies and the online database [4, 24-26]. The discrepancy between these data might be the cut-off of positivity and analysis method rather than ethnic differences. However, these results are in accordance with the study by Buyru et al. [22], who reported that RASSF1 is the most frequently methylated gene and is methylated in 56.4% of invasive ductal carcinomas using the same MS-MLPA method as in this study. However, in a recent study based on the Korean ethnicity, the methylation frequency of ductal carcinoma in situ was 89% by using MethylLight PCR analysis, which was determined as positive when the percentage of methylated reference was >4 [19]. Therefore, the method and cut-offs of positivity of methylation analyses are very important to reduce false positives due to inadequate conversion of non-methylated cytosine to uracil and mis-priming when high numbers of PCR cycles or nested primers are used [5, 6]. Optimal cut-off determination can result in over-fitting and false-discovery. In the future, we will validate our findings by using a larger sample set from clinical trials and develop biomarkers for clinical use. RASSF1 hypermethylation has suggested lymph node involvement, but the association between hypermethylation and nodal involvement was statistically insignificant (P=0.073). RASSF1 methylation has been previously shown to be associated with nodal metastasis in patients with breast cancer [27]. Further, the frequency of RASSF1 methylation was shown to be higher in various metastatic sites as compared to the primary tumors [28], suggesting the potential of RASSF1 hypermethylation as a predictor for lymph node metastasis in breast cancer.

CDKN2B was the most frequently hypermethylated gene in corresponding normal breast tissues and the third most, in cancerous tissues. The CDKN2B hypermethylation has been frequently noted in various cancers, such as leukemia, lymphoma, colorectal cancer, brain cancer, liver cancer, gastric cancer, multiple myeloma, ovarian cancer, and lung cancer [29-32]. In cancerous, para-cancerous, and non-cancerous tissues in hepatocellular carcinoma, CDKN2B hypermethylation occurred at frequencies of 50%, 40%, and 25%, respectively [33]. The frequencies of CDKN2B promoter methylation in corresponding normal and cancerous tissues in colorectal cancer were reported to be 6.8% (6/88) and 26.1% (23/88), respectively [34]. Both studies suggested that CDKN2B promoter methylation might be an early event in hepatocarcinogenesis or colorectal cancer [33, 34]. This study demonstrates that CDKN2B promoter methylation in corresponding normal tissues in breast cancer is a frequent event and CDKN2B hypermethylation may be an early event of breast carcinogenesis in Korean patients with breast cancer.

The APC gene is the second most hypermethylated gene in cancerous tissues and the frequency was 31.7% (19/60); hypermethylation of this gene was not observed in corresponding normal tissues. Similar reports indicated that hypermethylation of the APC promoter was detected in 18 of 50 (36%) primary breast cancers and in none of the 21 non-cancerous breast tissue samples [35]. These results indicate that APC hypermethylation is a cancer-specific change. In addition, APC hypermethylation was associated with lymph node involvement in this study (P=0.034). Therefore, APC hypermethylation might result in more aggressive behavior, which can potentially become a useful prognostic indicator warranting a more aggressive therapeutic approach.

BRCA1 hypermethylation was the third most hypermethylated gene (5%) in the corresponding normal breast tissue and the fifth most (10%) in cancerous tissues in this study. Although there was no statistical significance between the clinicopathologic characteristics and BRCA1 hypermethylation using multivariate logistic regression analysis, BRCA1 hypermethylation was associated with negative ER expression (P=0.004), negative PR expression (P=0.014), negative BCL-2 expression, and high histologic grade (P=0.013). Methylation in breast cancer has long been linked to hormone regulation, but this correlation has not been established yet. The status of both ER and PR are very important to help determine patients who would benefit the most from hormone therapy. BRCA1 hypermethylation is more frequent among breast cancer patients with negative ER and negative PR expression, and this study suggests that hypermethylation of the gene promoter in cancerous tissues may be associated with hormone expression.

Detection of promoter CpG island hypermethylation offers several advantages compared to other DNA alterations in cancer. These events may provide ideal biomarkers for molecular diagnosis and early detection of cancer.

In conclusion, we have clearly demonstrated that normal-appearing breast tissue from the Korean patients with breast cancer exhibited frequent aberrant DNA methylation changes. This
study also suggests that gene methylation may be linked to various pathological features of breast cancer; however, this requires confirmation in a larger study group.

Authors’ Disclosures of Potential Conflicts of Interest

No potential conflicts of interest relevant to this article were reported.

Acknowledgements

This study was supported by a Biomedical Research Institute Grant (2010-02), Pusan National University Hospital, and grants from the Research Foundation of Gyeongsang National University Hospital, GNUHCRF-2010-005.

REFERENCES

1. The Korea Central Cancer Registry. Annual report of cancer statistics in Korea in 2009. Seoul: The Korean Ministry of Health and Welfare, 2011.
2. Li S, Rong M, Iacopetta B. DNA hypermethylation in breast cancer and its association with clinicopathological features. Cancer Lett 2006;237: 272-80.
3. Van De Voorde L, Speeckaert R, Van Gestel D, Bracke M, De Neve W, Delanghe J, et al. DNA methylation-based biomarkers in serum of patients with breast cancer. Mutat Res 2012;751:304-25.
4. Marzese DM, Hoon DS, Chong KK, Gago FE, Orozco JI, Tello OM, et al. DNA methylation index and methylation profile of invasive ductal breast tumors. J Mol Diagn 2012;14:613-22.
5. Cheol Kim D, Thorat MA, Lee MR, Cho SH, Vasiljevic N, Scibior-Benkowski D, et al. Quantitative DNA methylation and recurrence of breast cancer: a study of 30 candidate genes. Cancer Biomark 2012;11:75-88.
6. Zhu W, Qin W, Hewett JE, Sauter ER. Quantitative evaluation of DNA hypemethylation in malignant and benign breast tissue and fluids. Int J Cancer 2010;126:474-82.
7. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 2002;21:5427-40.
8. Esteller M. Cancer epigenetics: DNA methylation and chromatin alterations in human cancer. Adv Exp Med Biol 2003;532:39-49.
9. Widschwendter M and Jones PA. DNA methylation and breast carcinogenesis. Oncogene 2002;21:5462-82.
10. Xu J, Shetty PB, Feng W, Chenault C, Bast RC Jr, Issa JP, et al. Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome. BMC Cancer 2012;12:243.
11. Wang S, Dorsey TH, Terunuma A, Kittles RA, Ambts S, Kwabi-Addo B. Relationship between tumor DNA methylation status and patient characteristics in African-American and European-American women with breast cancer. PLoS One 2012;7:e37928.
12. van Hoesel AQ, van de Velde CJ, Kuppen PJ, Putter H, de Kruif EM, van Nes JG, et al. Primary tumor classification according to methylation pattern is prognostic in patients with early stage ER-negative breast cancer. Breast Cancer Res Treat 2012;131:859-69.
13. Zserga A, Michalopoulou NV, Levidakou G, Korkolopoulou P, Zografos G, Patsouris E, et al. Association of aberrant DNA methylation with clinicopathological features in breast cancer. Oncol Rep 2012;27:1630-8.
14. Szfy M. DNA methylation signatures for breast cancer classification and prognosis. Genome Med 2012;4:26.
15. Elston CW and Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 2002;41:154-61.
16. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/Colege of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-45.
17. Nygren AO, Ameziane N, Duarte HM, Vijeelaa RN, Waisfisz Q, Hess CJ, et al. Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic Acids Res 2005;33:e128.
18. Van der Auwera I, Bovie C, Svensson C, Trinh XB, Limarne R, van Dam P, et al. Quantitative methylation profiling in tumor and matched morphologically normal tissues from breast cancer patients. BMC Cancer 2010;10:97.
19. Park SY, Kwon HJ, Lee HE, Ryu HS, Kim SW, Kim JH, et al. Promoter CpG island hypermethylation during breast cancer progression. Virchows Arch 2011;458:73-84.
20. Kim JH, Shin MH, Kweon SS, Park MH, Yoon JH, Lee JS, et al. Evaluation of promoter hypermethylation detection in serum as a diagnostic tool for breast carcinoma in Korean women. Gynecol Oncol 2010;118:176-81.
21. Marzese DM, Gago FE, Vargas-Roig LM, Roque M. Simultaneous analysis of the methylation profile of 26 cancer related regions in invasive breast carcinomas by MS-MLPA and drMS-MLPA. Mol Cell Probes 2010;24:271-80.
22. Buyru N, Altinisik J, Ozdemir F, Demokan S, Dalay N. Methylation profiles in breast cancer. Cancer Invest 2009;27:307-12.
23. Marzese DM, Gago FE, Vargas-Roig LM, Roque M. Simultaneous analysis of the methylation profile of 26 cancer related regions in invasive breast carcinomas by MS-MLPA and drMS-MLPA. Mol Cell Probes 2010;24:271-80.
24. Dammann R, Yang G, Pfeifer GP. Hypermethylation of the CpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res 2001;61:3105-9.
25. Honorio S, Agathanggelou A, Schuermann M, Pankow W, Viccata P, Mahler ER, et al. Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients. Oncogene 2003;22:147-50.
26. Yeo W, Wong WL, Wong N, Law BK, Tse GM, Zhong S. High frequency of promoter hypermethylation of RASSF1A in tumors and non-tumourous tissue of breast cancer. Pathology 2005;37:125-30.
27. Müller HM, Widschwendter A, Fieg hl, Ivarsson L, Goebel G, Perkmann E, et al. DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res 2003;63:7641-5.
28. Mehrotra J, Vali M, McVeigh M, Kominsky SL, Fackler MU, Lahto-Domenici J, et al. Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain, and lung. Clin Cancer Res 2004;10:3104-9.
29. Dodge JE, Munson C, List AF. KG-1 and KG-1a model the p15 CpG island methylation observed in acute myeloid leukemia patients. Leuk Res 2001;25:917-25.
30. Aggerholm A, Guldberg P, Høkland M, Høkland P. Extensive intra- and interindividual heterogeneity of p15INK4B methylation in acute myeloid
leukemia. Cancer Res 1999;59:436-41.
31. Herman JG, Jen J, Merlo A, Baylin SB. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res 1996;56:722-7.
32. Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2003;17:1813-9.
33. Qin Y, Liu JY, Li B, Sun ZL, Sun ZF. Association of low p16INK4a and p15INK4b mRNAs expression with their CpG islands methylation with human hepatocellular carcinogenesis. World J Gastroenterol 2004;10:1276-80.
34. Ishiguro A, Takahata T, Saito M, Yoshiya G, Tamura Y, Sasaki M, et al. Influence of methylated p15 and p16 genes on clinicopathological features in colorectal cancer. J Gastroenterol Hepatol 2006;21:1334-9.
35. Jin Z, Tamura G, Tsuchiya T, Sakata K, Kashiwaba M, Osakabe M, et al. Adenomatous polyposis coli (APC) gene promoter hypermethylation in primary breast cancers. Br J Cancer 2001;85:69-73.